Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05116176
Other study ID # 2021P000054
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date December 15, 2021
Est. completion date March 2025

Study information

Verified date August 2023
Source Beth Israel Deaconess Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective cohort study of older patients receiving implantable cardioverter-defibrillators. The purpose of the TRACER-ICD study is to conduct a prospective cohort investigation with the goal of 500 patients age >65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs). Patients will be followed quarterly for 18 months with interviews, electronic record review, and remote monitoring to characterize clinical and functional trajectories following device implantation, with permission for extended electronic follow-up for up to 10 years (Aim 1). This cohort will support validation and refinement of an established model for predicting personalized outcome profiles for ICD therapies and death (Aim 2). Lastly, we will combine electronic record review with semi-structured interviews with patients and physicians to evaluate physician and patient experiences with a prototype individualized shared decision-making (SDM) tool (Aim 3).


Description:

Study Objectives and Design The specific aims, applicable methods, and main hypotheses of the TRACER-ICD study are as follows: Aim 1: To characterize the clinical course of patients aged >65 after ICD implantation by establishing a multicenter prospective cohort (N=500). Baseline (verbal and in-person) and quarterly (phone, electronic health records [EHR], remote monitoring) data collected up to 18 months or death will include: a. geriatric assessments (e.g. frailty, cognition,1 functional status; b. comorbidities; c. quality of life and symptom burden; d. health services use; e. SDM history; and f. ICD-recorded physical activity (minutes/day). Factors associated with death and poor quality of life will be identified. Group-based trajectory modeling will identify patient clusters with distinct trajectories of functional status and quality of life following ICD implantation. H1: A model integrating frailty and clinical factors will predict (a) death, (b) poor quality of life, and (c) unfavorable functional trajectories after ICD implantation. Aim 2: To validate a personalized prediction model of treatment outcomes of ICDs. We will apply our established semi-competing risks approach5 to the prospective cohort, enriched by the baseline geriatric assessments, to predict individual patients' probabilities of the following outcome profiles at 6, 12, and 18 months post-implant: a. death without prior shock, b. death with prior shock, c. survival without prior shock, and d. survival with prior shock. The independent contribution of frailty, cognitive dysfunction, baseline quality of life, and functional status (e.g. total deficits in ADL and IADL) to model performance will be evaluated. H2: Addition of frailty, cognitive dysfunction, quality of life, and functional status to a model with cardiovascular variables will significantly improve model performance as assessed by area under the curve (AUC). Aim 3: To identify optimal strategies for incorporating personalized outcome profiles into SDM. The main cohort's baseline interview and EHR review will provide quantitative data on past SDM tools used by physicians. We will develop a prototype individualized version of the Colorado SDM tool that incorporates 18-month outcome profiles using our semi-competing risk model. We will perform semi-structured interviews of cardiologists (N=20) as well as patients (N=20) recruited from the main cohort regarding process mapping of SDM from clinic to implant procedure, including timing, content, format preferences, and impressions of the prototype individualized tool.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 500
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Patients scheduled for ICD implantation will be identified at participating sites by site staff. Eligibility criteria will include the following, all of which must be met by all participants for participation: 1. Patient receiving new primary prevention ICD (single, dual chamber, or subcutaneous system) 2. Age >65 years 3. English-speaking (assessment instruments are only available/validated in English) 4. Sufficient cognitive ability to provide consent (i.e. answer simple questions on study participation, purpose and procedures) Candidates meeting the following exclusion criteria at baseline will be excluded from study participation: 1. Receipt of cardiac resynchronization therapy device 2. Participation in another investigational drug or intervention trial expected to influence any of the outcomes of interest in this study 3. Current drug or alcohol use or dependence that, in the opinion of the Site Principle Investigator, would interfere with adherence to study requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Implantable cardioverter-defibrillators
500 patients age >65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts

Sponsors (7)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center Emory University, Hebrew SeniorLife, Mayo Clinic, Saint Luke's Health System, University of Colorado, Denver, University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Trajectories after ICD implantation Group-based trajectory modeling will identify patient clusters with distinct trajectories of functional status and quality of life following ICD implantation. Patients will be followed quarterly for 18 months or to death.
Primary Outcomes after ICD Implantation Death/Poor Quality of Life (combined endpoint) Up to 18 months
Primary Semi-competing risks model of deaths and/or ICD shocks Personalized outcome profiles for death +/- ICD shocks Up to 18 months
See also
  Status Clinical Trial Phase
Terminated NCT02243696 - Protego DF4 Post Approval Registry
Completed NCT02902458 - Psychological Intervention modifiEs Outcome of Patients With implAntable Cardioverter dEfibrillator: The PEACE Study N/A
Recruiting NCT02058771 - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Completed NCT02232204 - Sleep and Ventricular Arrhythmias Study Phase 2
Recruiting NCT05302115 - S-ICD French Cohort Study (HONEST)
Completed NCT05101720 - Ultrasound Guided Axillary Access vs Standard Fluoroscopic Technique for Cardiac Lead Implantation: ZEROFLUOROAXI TRIAL N/A
Active, not recruiting NCT03884608 - Analysis of Both Sex and Device Specific Factors on Outcomes in Patients With Non-Ischemic Cardiomyopathy
Completed NCT02787291 - A Clinical Evaluation of the Durata or Optisure High Voltage Leads and Ellipse VR ICD Undergoing MRI, an IDE Study N/A
Completed NCT02064192 - Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe
Terminated NCT03103503 - Plexa ICD Lead Registry
Recruiting NCT05855135 - Assessment of Combined CCM and ICD Device in HFrEF N/A
Not yet recruiting NCT06388382 - Investigation of the Audible ICD Alert Tone
Recruiting NCT04858672 - Shock Testing to Unmask RV Lead and GEnerator Malfunction in ICD Patients: the SURGE-ICD Registry
Completed NCT03209726 - Assessment of S-ICD Eligibility With 12-Lead ECG
Active, not recruiting NCT04981496 - Novel ICD Arrhythmia Detection Algorithm
Recruiting NCT05645965 - Association of Obesity and Cardiovascular Outcomes in Patients With Implantable Cardioverter-defibrillator (ICD)
Completed NCT03544489 - Implementing Exercise After an (ICD) N/A
Completed NCT03210883 - Global Electrical Heterogeneity and Clinical Outcomes
Completed NCT02491853 - The Gulf Implantable Cardioverter-Defibrillator Registry N/A
Completed NCT01944514 - Implantable Cardioverter Defibrillators - Improving Risk Stratification N/A